TY - JOUR AU - Coughlan, D. PY - 2017 DA - 2017// TI - Treatment and survival of childhood neuroblastoma: evidence from a population-based study in the United States JO - Pediatr Hematol Oncol VL - 34 UR - https://doi.org/10.1080/08880018.2017.1373315 DO - 10.1080/08880018.2017.1373315 ID - Coughlan2017 ER - TY - JOUR AU - Matthay, K. K. PY - 2016 DA - 2016// TI - Neuroblastoma JO - Nat Rev Dis Primers VL - 2 UR - https://doi.org/10.1038/nrdp.2016.78 DO - 10.1038/nrdp.2016.78 ID - Matthay2016 ER - TY - JOUR AU - Maris, J. M. PY - 2007 DA - 2007// TI - Neuroblastoma JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60983-0 DO - 10.1016/S0140-6736(07)60983-0 ID - Maris2007 ER - TY - JOUR AU - Yu, A. L. PY - 2010 DA - 2010// TI - Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0911123 DO - 10.1056/NEJMoa0911123 ID - Yu2010 ER - TY - STD TI - Voeller, JS PM, Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. J Pediatr Hematol Oncol, 2018. ID - ref5 ER - TY - JOUR AU - Kramer, K. PY - 1998 DA - 1998// TI - Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma JO - Clin Cancer Res VL - 4 ID - Kramer1998 ER - TY - JOUR AU - Schulz, G. PY - 1984 DA - 1984// TI - Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients JO - Cancer Res VL - 44 ID - Schulz1984 ER - TY - JOUR AU - Yang, R. K. AU - Sondel, P. M. PY - 2010 DA - 2010// TI - Anti-GD2 strategy in the treatment of neuroblastoma JO - Drugs Future VL - 35 UR - https://doi.org/10.1358/dof.2010.035.08.1513490 DO - 10.1358/dof.2010.035.08.1513490 ID - Yang2010 ER - TY - JOUR AU - Perez Horta, Z. AU - Goldberg, J. L. AU - Sondel, P. M. PY - 2016 DA - 2016// TI - Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy JO - Immunotherapy VL - 8 UR - https://doi.org/10.2217/imt-2016-0021 DO - 10.2217/imt-2016-0021 ID - Perez Horta2016 ER - TY - JOUR AU - Morris, Z. S. PY - 2016 DA - 2016// TI - In situ tumor vaccination by combining local radiation and tumor-specific antibody or Immunocytokine treatments JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-15-2644 DO - 10.1158/0008-5472.CAN-15-2644 ID - Morris2016 ER - TY - JOUR AU - Morris, Z. S. PY - 2018 DA - 2018// TI - Tumor-specific inhibition of in situ vaccination by distant untreated tumor sites JO - Cancer Immunol Res VL - 6 UR - https://doi.org/10.1158/2326-6066.CIR-17-0353 DO - 10.1158/2326-6066.CIR-17-0353 ID - Morris2018 ER - TY - JOUR AU - Rakhmilevich, A. L. PY - 2017 DA - 2017// TI - Effective combination of innate and adaptive immunotherapeutic approaches in a mouse melanoma model JO - J Immunol VL - 198 UR - https://doi.org/10.4049/jimmunol.1601255 DO - 10.4049/jimmunol.1601255 ID - Rakhmilevich2017 ER - TY - JOUR AU - Lawrence, M. S. PY - 2013 DA - 2013// TI - Mutational heterogeneity in cancer and the search for new cancer-associated genes JO - Nature VL - 499 UR - https://doi.org/10.1038/nature12213 DO - 10.1038/nature12213 ID - Lawrence2013 ER - TY - JOUR AU - Maleki Vareki, S. PY - 2018 DA - 2018// TI - High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0479-7 DO - 10.1186/s40425-018-0479-7 ID - Maleki Vareki2018 ER - TY - JOUR AU - Alexandrov, L. B. PY - 2013 DA - 2013// TI - Signatures of mutational processes in human cancer JO - Nature VL - 500 UR - https://doi.org/10.1038/nature12477 DO - 10.1038/nature12477 ID - Alexandrov2013 ER - TY - JOUR AU - Gubin, M. M. PY - 2014 DA - 2014// TI - Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13988 DO - 10.1038/nature13988 ID - Gubin2014 ER - TY - JOUR AU - Schumacher, T. N. AU - Schreiber, R. D. PY - 2015 DA - 2015// TI - Neoantigens in cancer immunotherapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa4971 DO - 10.1126/science.aaa4971 ID - Schumacher2015 ER - TY - JOUR AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Allen, E. M. PY - 2015 DA - 2015// TI - Genomic correlates of response to CTLA-4 blockade in metastatic melanoma JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad0095 DO - 10.1126/science.aad0095 ID - Allen2015 ER - TY - JOUR AU - Pistoia, V. PY - 2013 DA - 2013// TI - Immunosuppressive microenvironment in neuroblastoma JO - Front Oncol VL - 3 UR - https://doi.org/10.3389/fonc.2013.00167 DO - 10.3389/fonc.2013.00167 ID - Pistoia2013 ER - TY - JOUR AU - Marshall, H. T. AU - Djamgoz, M. B. A. PY - 2018 DA - 2018// TI - Immuno-oncology: emerging targets and combination therapies JO - Front Oncol VL - 8 UR - https://doi.org/10.3389/fonc.2018.00315 DO - 10.3389/fonc.2018.00315 ID - Marshall2018 ER - TY - JOUR AU - Wedekind, M. F. PY - 2018 DA - 2018// TI - Pediatric Cancer immunotherapy: opportunities and challenges JO - Paediatr Drugs VL - 20 UR - https://doi.org/10.1007/s40272-018-0297-x DO - 10.1007/s40272-018-0297-x ID - Wedekind2018 ER - TY - JOUR AU - Goodman, A. M. PY - 2017 DA - 2017// TI - Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0386 DO - 10.1158/1535-7163.MCT-17-0386 ID - Goodman2017 ER - TY - JOUR AU - Norris, M. D. PY - 2000 DA - 2000// TI - Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model JO - Med Pediatr Oncol VL - 35 UR - https://doi.org/3.0.CO;2-P DO - 3.0.CO;2-P ID - Norris2000 ER - TY - JOUR AU - Yang, R. K. PY - 2013 DA - 2013// TI - Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival JO - Cancer Immunol Immunother VL - 62 UR - https://doi.org/10.1007/s00262-013-1430-x DO - 10.1007/s00262-013-1430-x ID - Yang2013 ER - TY - JOUR AU - Fowler, C. L. PY - 1990 DA - 1990// TI - Postoperative immunotherapy of murine C1300-neuroblastoma JO - J Pediatr Surg VL - 25 UR - https://doi.org/10.1016/0022-3468(90)90408-2 DO - 10.1016/0022-3468(90)90408-2 ID - Fowler1990 ER - TY - JOUR AU - Uphoff, C. C. AU - Drexler, H. G. PY - 2002 DA - 2002// TI - Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines JO - In Vitro Cell Dev Biol Anim VL - 38 UR - https://doi.org/2.0.CO;2 DO - 2.0.CO;2 ID - Uphoff2002 ER - TY - JOUR AU - Navid, F. PY - 2014 DA - 2014// TI - Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.50.4423 DO - 10.1200/JCO.2013.50.4423 ID - Navid2014 ER - TY - JOUR AU - Gillies, S. D. PY - 1992 DA - 1992// TI - Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells JO - Proc Natl Acad Sci U S A VL - 89 UR - https://doi.org/10.1073/pnas.89.4.1428 DO - 10.1073/pnas.89.4.1428 ID - Gillies1992 ER - TY - JOUR AU - Selby, M. J. PY - 2013 DA - 2013// TI - Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0013 DO - 10.1158/2326-6066.CIR-13-0013 ID - Selby2013 ER - TY - JOUR AU - Dewan, M. Z. PY - 2009 DA - 2009// TI - Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-0265 DO - 10.1158/1078-0432.CCR-09-0265 ID - Dewan2009 ER - TY - JOUR AU - Twyman-Saint Victor, C. PY - 2015 DA - 2015// TI - Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer JO - Nature VL - 520 UR - https://doi.org/10.1038/nature14292 DO - 10.1038/nature14292 ID - Twyman-Saint Victor2015 ER - TY - JOUR AU - Chaudhary, A. PY - 2012 DA - 2012// TI - TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types JO - Cancer Cell VL - 21 UR - https://doi.org/10.1016/j.ccr.2012.01.004 DO - 10.1016/j.ccr.2012.01.004 ID - Chaudhary2012 ER - TY - JOUR AU - Chaudhary, A. AU - Croix, B. S. PY - 2012 DA - 2012// TI - Selective blockade of tumor angiogenesis JO - Cell Cycle VL - 11 UR - https://doi.org/10.4161/cc.20374 DO - 10.4161/cc.20374 ID - Chaudhary2012 ER - TY - JOUR AU - St Croix, B. PY - 2000 DA - 2000// TI - Genes expressed in human tumor endothelium JO - Science VL - 289 UR - https://doi.org/10.1126/science.289.5482.1197 DO - 10.1126/science.289.5482.1197 ID - St Croix2000 ER - TY - JOUR AU - Vargas, M. PY - 2012 DA - 2012// TI - Broad expression analysis of human ANTXR1/TEM8 transcripts reveals differential expression and novel splizce variants JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0043174 DO - 10.1371/journal.pone.0043174 ID - Vargas2012 ER - TY - JOUR AU - Connor, J. P. PY - 2004 DA - 2004// TI - Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer JO - J Immunother VL - 27 UR - https://doi.org/10.1097/00002371-200405000-00005 DO - 10.1097/00002371-200405000-00005 ID - Connor2004 ER - TY - BOOK AU - Li, H. PY - 2013 DA - 2013// TI - Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM ID - Li2013 ER - TY - JOUR AU - McKenna, A. PY - 2010 DA - 2010// TI - The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data JO - Genome Res VL - 20 UR - https://doi.org/10.1101/gr.107524.110 DO - 10.1101/gr.107524.110 ID - McKenna2010 ER - TY - JOUR AU - Cibulskis, K. PY - 2013 DA - 2013// TI - Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples JO - Nat Biotechnol VL - 31 UR - https://doi.org/10.1038/nbt.2514 DO - 10.1038/nbt.2514 ID - Cibulskis2013 ER - TY - JOUR AU - Kowalczyk, A. PY - 2007 DA - 2007// TI - Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery JO - Cancer Immunol Immunother VL - 56 UR - https://doi.org/10.1007/s00262-007-0289-0 DO - 10.1007/s00262-007-0289-0 ID - Kowalczyk2007 ER - TY - JOUR AU - Kroesen, M. PY - 2014 DA - 2014// TI - A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma JO - Int J Cancer VL - 134 UR - https://doi.org/10.1002/ijc.28463 DO - 10.1002/ijc.28463 ID - Kroesen2014 ER - TY - JOUR AU - Sivan, A. PY - 2015 DA - 2015// TI - Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy JO - Science VL - 350 UR - https://doi.org/10.1126/science.aac4255 DO - 10.1126/science.aac4255 ID - Sivan2015 ER - TY - JOUR AU - Ribas, A. PY - 2015 DA - 2015// TI - Releasing the brakes on Cancer immunotherapy JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMp1510079 DO - 10.1056/NEJMp1510079 ID - Ribas2015 ER - TY - JOUR AU - Alexander, J. L. PY - 2017 DA - 2017// TI - Gut microbiota modulation of chemotherapy efficacy and toxicity JO - Nat Rev Gastroenterol Hepatol VL - 14 UR - https://doi.org/10.1038/nrgastro.2017.20 DO - 10.1038/nrgastro.2017.20 ID - Alexander2017 ER - TY - JOUR AU - Pitt, J. M. PY - 2016 DA - 2016// TI - Fine-tuning Cancer immunotherapy: optimizing the gut microbiome JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-16-0448 DO - 10.1158/0008-5472.CAN-16-0448 ID - Pitt2016 ER - TY - JOUR AU - Roy, S. AU - Trinchieri, G. PY - 2017 DA - 2017// TI - Microbiota: a key orchestrator of cancer therapy JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2017.13 DO - 10.1038/nrc.2017.13 ID - Roy2017 ER - TY - JOUR AU - Vetizou, M. PY - 2015 DA - 2015// TI - Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad1329 DO - 10.1126/science.aad1329 ID - Vetizou2015 ER - TY - JOUR AU - Cheng, A. J. PY - 2007 DA - 2007// TI - Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2007.03.008 DO - 10.1016/j.ejca.2007.03.008 ID - Cheng2007 ER - TY - JOUR AU - Voort, T. J. PY - 2013 DA - 2013// TI - Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces T cell-independent, local and systemic antitumor effects in mice JO - J Immunother VL - 36 UR - https://doi.org/10.1097/CJI.0b013e3182780f61 DO - 10.1097/CJI.0b013e3182780f61 ID - Voort2013 ER - TY - JOUR AU - Vanpouille-Box, C. PY - 2017 DA - 2017// TI - DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/ncomms15618 DO - 10.1038/ncomms15618 ID - Vanpouille-Box2017 ER -